Development and First Validation of a Disease Activity Score for Gout

Carlo A. Scirè, Greta Carrara, Cinzia Viroli, Marco A. Cimmino, William J. Taylor, Maria Manara, Marcello Govoni, Fausto Salaffi, Leonardo Punzi, Carlomaurizio Montecucco, Marco Matucci-Cerinic, Giovanni Minisola, Alarico Ariani, Alessandra Galossi, Ciro Lauriti, Elena Fracassi, Luca Idolazzi, Marco Bardelli, Enrico Selvi, Enrico Tirri & 31 others Federica Furini, Flora Inverardi, Andrea Calabrò, Francesco Porta, Raffaele Bittelli, Francesco Venturino, Franco Capsoni, Immacolata Prevete, Giandomenico Sebastiani, Carlo Selmi, Gianluigi Fabbriciani, Giovanni D'Avola, Giulia Botticella, Francesca Serale, Giulia Seminara, Giuseppe D'Alessandro, Leonardo Santo, Lorena Longato, Eleonora Zaccara, Luigi Sinigaglia, Marco Atteritano, Marco Broggini, Marta Caprioli, Marta Favero, Salvatore Sallì, Marco Scarati, Simone Parisi, Nazzarena Malavolta, Stefania Corvaglia, Salvatore Scarpato, and the Study Group for the Kick-Off of the Italian Network for Gout Study

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To develop a new composite disease activity score for gout and provide its first validation. Methods: Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used. Construct- and criterion-related validity were tested. External validation on an independent sample is reported. Results: Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient- and physician-reported measures of active disease (construct validity). The results were reproduced in the external sample. Conclusion: This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.

Original languageEnglish
Pages (from-to)1530-1537
Number of pages8
JournalArthritis Care and Research
Volume68
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Gout
Uric Acid
Joints
Discriminant Analysis
Statistical Factor Analysis
Linear Models
Rheumatology
Pain Measurement
Serum
Visual Analog Scale
Arthritis
Regression Analysis
Outcome Assessment (Health Care)
Physicians

ASJC Scopus subject areas

  • Rheumatology

Cite this

Scirè, C. A., Carrara, G., Viroli, C., Cimmino, M. A., Taylor, W. J., Manara, M., ... and the Study Group for the Kick-Off of the Italian Network for Gout Study (2016). Development and First Validation of a Disease Activity Score for Gout. Arthritis Care and Research, 68(10), 1530-1537. https://doi.org/10.1002/acr.22844

Development and First Validation of a Disease Activity Score for Gout. / Scirè, Carlo A.; Carrara, Greta; Viroli, Cinzia; Cimmino, Marco A.; Taylor, William J.; Manara, Maria; Govoni, Marcello; Salaffi, Fausto; Punzi, Leonardo; Montecucco, Carlomaurizio; Matucci-Cerinic, Marco; Minisola, Giovanni; Ariani, Alarico; Galossi, Alessandra; Lauriti, Ciro; Fracassi, Elena; Idolazzi, Luca; Bardelli, Marco; Selvi, Enrico; Tirri, Enrico; Furini, Federica; Inverardi, Flora; Calabrò, Andrea; Porta, Francesco; Bittelli, Raffaele; Venturino, Francesco; Capsoni, Franco; Prevete, Immacolata; Sebastiani, Giandomenico; Selmi, Carlo; Fabbriciani, Gianluigi; D'Avola, Giovanni; Botticella, Giulia; Serale, Francesca; Seminara, Giulia; D'Alessandro, Giuseppe; Santo, Leonardo; Longato, Lorena; Zaccara, Eleonora; Sinigaglia, Luigi; Atteritano, Marco; Broggini, Marco; Caprioli, Marta; Favero, Marta; Sallì, Salvatore; Scarati, Marco; Parisi, Simone; Malavolta, Nazzarena; Corvaglia, Stefania; Scarpato, Salvatore; and the Study Group for the Kick-Off of the Italian Network for Gout Study.

In: Arthritis Care and Research, Vol. 68, No. 10, 01.10.2016, p. 1530-1537.

Research output: Contribution to journalArticle

Scirè, CA, Carrara, G, Viroli, C, Cimmino, MA, Taylor, WJ, Manara, M, Govoni, M, Salaffi, F, Punzi, L, Montecucco, C, Matucci-Cerinic, M, Minisola, G, Ariani, A, Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabrò, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, M, Broggini, M, Caprioli, M, Favero, M, Sallì, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S & and the Study Group for the Kick-Off of the Italian Network for Gout Study 2016, 'Development and First Validation of a Disease Activity Score for Gout', Arthritis Care and Research, vol. 68, no. 10, pp. 1530-1537. https://doi.org/10.1002/acr.22844
Scirè, Carlo A. ; Carrara, Greta ; Viroli, Cinzia ; Cimmino, Marco A. ; Taylor, William J. ; Manara, Maria ; Govoni, Marcello ; Salaffi, Fausto ; Punzi, Leonardo ; Montecucco, Carlomaurizio ; Matucci-Cerinic, Marco ; Minisola, Giovanni ; Ariani, Alarico ; Galossi, Alessandra ; Lauriti, Ciro ; Fracassi, Elena ; Idolazzi, Luca ; Bardelli, Marco ; Selvi, Enrico ; Tirri, Enrico ; Furini, Federica ; Inverardi, Flora ; Calabrò, Andrea ; Porta, Francesco ; Bittelli, Raffaele ; Venturino, Francesco ; Capsoni, Franco ; Prevete, Immacolata ; Sebastiani, Giandomenico ; Selmi, Carlo ; Fabbriciani, Gianluigi ; D'Avola, Giovanni ; Botticella, Giulia ; Serale, Francesca ; Seminara, Giulia ; D'Alessandro, Giuseppe ; Santo, Leonardo ; Longato, Lorena ; Zaccara, Eleonora ; Sinigaglia, Luigi ; Atteritano, Marco ; Broggini, Marco ; Caprioli, Marta ; Favero, Marta ; Sallì, Salvatore ; Scarati, Marco ; Parisi, Simone ; Malavolta, Nazzarena ; Corvaglia, Stefania ; Scarpato, Salvatore ; and the Study Group for the Kick-Off of the Italian Network for Gout Study. / Development and First Validation of a Disease Activity Score for Gout. In: Arthritis Care and Research. 2016 ; Vol. 68, No. 10. pp. 1530-1537.
@article{e0dd399d87a24978b7a7e552d86c8001,
title = "Development and First Validation of a Disease Activity Score for Gout",
abstract = "Objective: To develop a new composite disease activity score for gout and provide its first validation. Methods: Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used. Construct- and criterion-related validity were tested. External validation on an independent sample is reported. Results: Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79{\%}. Linear regression analysis identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient- and physician-reported measures of active disease (construct validity). The results were reproduced in the external sample. Conclusion: This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.",
author = "Scir{\`e}, {Carlo A.} and Greta Carrara and Cinzia Viroli and Cimmino, {Marco A.} and Taylor, {William J.} and Maria Manara and Marcello Govoni and Fausto Salaffi and Leonardo Punzi and Carlomaurizio Montecucco and Marco Matucci-Cerinic and Giovanni Minisola and Alarico Ariani and Alessandra Galossi and Ciro Lauriti and Elena Fracassi and Luca Idolazzi and Marco Bardelli and Enrico Selvi and Enrico Tirri and Federica Furini and Flora Inverardi and Andrea Calabr{\`o} and Francesco Porta and Raffaele Bittelli and Francesco Venturino and Franco Capsoni and Immacolata Prevete and Giandomenico Sebastiani and Carlo Selmi and Gianluigi Fabbriciani and Giovanni D'Avola and Giulia Botticella and Francesca Serale and Giulia Seminara and Giuseppe D'Alessandro and Leonardo Santo and Lorena Longato and Eleonora Zaccara and Luigi Sinigaglia and Marco Atteritano and Marco Broggini and Marta Caprioli and Marta Favero and Salvatore Sall{\`i} and Marco Scarati and Simone Parisi and Nazzarena Malavolta and Stefania Corvaglia and Salvatore Scarpato and {and the Study Group for the Kick-Off of the Italian Network for Gout Study}",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/acr.22844",
language = "English",
volume = "68",
pages = "1530--1537",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Development and First Validation of a Disease Activity Score for Gout

AU - Scirè, Carlo A.

AU - Carrara, Greta

AU - Viroli, Cinzia

AU - Cimmino, Marco A.

AU - Taylor, William J.

AU - Manara, Maria

AU - Govoni, Marcello

AU - Salaffi, Fausto

AU - Punzi, Leonardo

AU - Montecucco, Carlomaurizio

AU - Matucci-Cerinic, Marco

AU - Minisola, Giovanni

AU - Ariani, Alarico

AU - Galossi, Alessandra

AU - Lauriti, Ciro

AU - Fracassi, Elena

AU - Idolazzi, Luca

AU - Bardelli, Marco

AU - Selvi, Enrico

AU - Tirri, Enrico

AU - Furini, Federica

AU - Inverardi, Flora

AU - Calabrò, Andrea

AU - Porta, Francesco

AU - Bittelli, Raffaele

AU - Venturino, Francesco

AU - Capsoni, Franco

AU - Prevete, Immacolata

AU - Sebastiani, Giandomenico

AU - Selmi, Carlo

AU - Fabbriciani, Gianluigi

AU - D'Avola, Giovanni

AU - Botticella, Giulia

AU - Serale, Francesca

AU - Seminara, Giulia

AU - D'Alessandro, Giuseppe

AU - Santo, Leonardo

AU - Longato, Lorena

AU - Zaccara, Eleonora

AU - Sinigaglia, Luigi

AU - Atteritano, Marco

AU - Broggini, Marco

AU - Caprioli, Marta

AU - Favero, Marta

AU - Sallì, Salvatore

AU - Scarati, Marco

AU - Parisi, Simone

AU - Malavolta, Nazzarena

AU - Corvaglia, Stefania

AU - Scarpato, Salvatore

AU - and the Study Group for the Kick-Off of the Italian Network for Gout Study

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Objective: To develop a new composite disease activity score for gout and provide its first validation. Methods: Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used. Construct- and criterion-related validity were tested. External validation on an independent sample is reported. Results: Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient- and physician-reported measures of active disease (construct validity). The results were reproduced in the external sample. Conclusion: This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.

AB - Objective: To develop a new composite disease activity score for gout and provide its first validation. Methods: Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used. Construct- and criterion-related validity were tested. External validation on an independent sample is reported. Results: Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient- and physician-reported measures of active disease (construct validity). The results were reproduced in the external sample. Conclusion: This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.

UR - http://www.scopus.com/inward/record.url?scp=84988925885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988925885&partnerID=8YFLogxK

U2 - 10.1002/acr.22844

DO - 10.1002/acr.22844

M3 - Article

VL - 68

SP - 1530

EP - 1537

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 10

ER -